Overseas Expansion of Proprietary Products and the Biomaterials Business
First written in FY2021. 7 of 14 entries say "Advanced", first in FY2023. Latest entry: 2026-10-09.
The whole theme swung hardest in 2020: 3 of 21 companies on the "Worse" side.
10 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In March 2026, the Company entered into an agreement with South Korea’s LG Chem, Ltd. for the sale in South Korea and Thailand of dienogest, which the Company sells in Japan for indications including endometriosis.」
For overseas expansion of proprietary products, the company newly entered into an agreement for the sale of dienogest in South Korea and Thailand. - 2026-05-15AdvancedRevision of earnings forecasts
「In July 2025, we established Mochida Medical USA, Inc. in Tennessee, United States, as a subsidiary engaged in the sale and development of medical devices.」
Describes the establishment of a U.S. subsidiary as a specific organizational step toward overseas sales and development of medical devices. - FY2026-H1RestatedAnnual report
「In the biomaterials business, which we position as one of the next generation’s core businesses, we are advancing projects based on alginate.」
The company continues to position the biomaterials business as one of the next generation’s core businesses and advance projects based on alginate. - FY2025AdvancedAnnual report
「ReFeel, a nerve regeneration conduit, received 510(k) clearance in the United States, and sales began for the purpose of collecting clinical data. The Company also entered into agreements relating to the sale of Epadel in China, South Korea, the ASEAN region and Taiwan, expanding the countries in which it is marketed.」
In the biomaterials business, the company proceeded with obtaining US 510(k) clearance for ReFeel and launching sales. For overseas expansion of proprietary products, it reports expanding the countries in which Epadel is marketed to include China, South Korea, the ASEAN region and Taiwan. - FY2025-H1RestatedAnnual report
「In the biomaterials business, which we position as one of the next generation’s core businesses, we are advancing projects based on alginate. Research and development expenses for the current interim consolidated accounting period were ¥4,776 million.」
The company continues to position the biomaterials business as one of the next generation’s core businesses and advance projects based on alginate. - FY2024AdvancedAnnual report
「Specifically, during fiscal 2023, toward the “Vision for 2031,” we deliberated on and decided matters including entering into an agreement with Meiji Seika Pharma Co., Ltd. for the sale of Epadel in China, filing a 510(k) application in the United States for a nerve regeneration conduit (generic name: Nerve Cuff), and organizational changes, including establishing an Overseas Business Office, in anticipation of overseas business expansion.」
The company reports specific progress in overseas expansion and next-generation businesses, including the Epadel sales agreement in China, the US 510(k) application for Nerve Cuff, and the establishment of an Overseas Business Office. - FY2024-Q3RestatedAnnual report
「In the biomaterials business, which we position as one of the next generation’s core businesses, we are advancing projects based on alginate.」
The company continues its policy of positioning the biomaterials business as one of the next generation’s core businesses and advancing projects based on alginate. - FY2024-Q2RestatedAnnual report
「In the biomaterials business, which we position as one of the next generation’s core businesses, we are advancing projects based on alginate.」
The company continues its policy of positioning the biomaterials business as one of the next generation’s core businesses and advancing projects based on alginate. - FY2024-Q1RestatedAnnual report
「In the biomaterials business, which we position as one of the next generation’s core businesses, we are advancing projects based on alginate.」
The company continues its policy of positioning the biomaterials business as one of the next generation’s core businesses and advancing projects based on alginate. - FY2023AdvancedAnnual report
「In the biomaterials business, we advanced the project toward the launch of dMD-001, a material for treating articular cartilage damage, during the period covered by the medium-term management plan.」
The company reports progress on the project to launch dMD-001 during the period covered by the medium-term management plan in the biomaterials business. - FY2022RestatedAnnual report
「We will actively invest in business activities linked to our future competitiveness. We will work to expand and advance the biomaterials business and bring products to market at an early stage.」
The company continues, under the 22-24 Medium-Term Management Plan, its policy of positioning the biomaterials business as one of the next generation’s core businesses and working to expand and advance it and bring products to market at an early stage. - FY2021First statedAnnual report
「To build the next generation of core businesses, we will actively invest in business activities linked to our future competitiveness. In drug discovery research, we will enhance our development pipeline by introducing early-stage development candidates through open innovation and other initiatives. We will also pursue the overseas expansion of our proprietary products and the biomaterials business.」
The 21-23 Medium-Term Management Plan explicitly identifies the overseas expansion of proprietary products and the biomaterials business as new initiatives to build the next generation of core businesses.